Momentum leaders · current
US momentum leaders — June 2026
As of 2026-06-12
June's screen is an AI-infrastructure tape. The largest three-month moves belong to the semiconductor and AI-server complex VSH (+245.879%), MRVL (+226.167%), ALAB (+210.807%) and DELL (+164.239%) with SNOW and HPE rounding out the software-and-gear flank. VSXY (+75.05% over one month) tops the score outright and CBRL (+63.972%) hands consumer cyclicals a second seat, while GENI and WGS post the freshest acceleration off lower three-month bases. With the regime turning RISK-ON, breadth at 60.6% above the 200-EMA and SPX +8.5% over that line, leadership parked in the highest-beta corner of tech says appetite, not defense, is setting the bid VIX still elevated at 19.44 notwithstanding.
Hillary Super turnaround confirmed by a +47% earnings blowoff (Q1 adj EPS $0.60 vs $0.32, comps +13%, FY op-income guide hiked to $550–580M). But…
AI-connectivity ACCEL but mid-correction knife after -11.4% Broadcom de-rate, beta 3.96, ~25% above avg PT; correlated dup of MRVL/TSM.
AI-enterprise ACCELERATING but own parabola cracked ~20% off the $475 ATH, sliced the low-$400s base; wait for a higher-low re-base, SNOW is our…
Legacy-diner turnaround confirmed by the 2026-06-09 Q3 beat and raised FY26 guide ($3.27–3.30B vs $3.25B est); analyst upgrades clustering (WFC OW…
Fresh entry. Price ran ~+6% past it; the post-mortem's lesson is to FUND cluster-confirmed HIGH names. Theme is ACCELERATING (0.91),…
Picks-and-shovels sports-data toll-booth under the prediction-market boom; narrative accelerating since the June 10 Polymarket/Liga MX data deal,…
Freight/LTL-recovery momentum nearly tripled ARCB off its $59 low to a fresh all-time-high $173 (June 12), but the name now trades ~14% above the…
Busted-growth genomics name: the May 4 print cut FY26 guide 12% and broke reimbursement (ARR ~$3,300, ~$200 light). Price has doubled off the $32…
Analog ACCELERATING tag but ZERO AI/HBM exposure (auto-cycle), post-catalyst momentum chase, broken quote prior session APH is the cleaner analog…
A narrative accelerating on FUNDAMENTALS: Q1 FY27 product rev $1.33B +34% (re-accel from +30%), RPO +38%, FY27 guide raised to $5.84B, Cortex Code…
Spectrum re-rating already paid: FCC's 2026-02-18 final rule lifting 900 MHz broadband to 10 MHz (implied $2.5–7B+ value) drove a ~3.7x run to the…
AI-server ACCELERATING theme but own setup failed +25% record blowoff round-tripped to ~$49 gap-fill, catalyst spent to ~Sept.
Busted-IPO turnaround: down from the $23.50 Sept-2025 IPO to a $5.74 low, now doubled off lows on a Q1 profitability inflection (first GAAP…
Broken growth (new patient starts -10-20% seq) bouncing into ADA on RSI 82.3 parabolic off a busted base; litigation circling event-relief, not a…
Identity-software momentum continuation: OKTA gapped to a 52-week high on a Q1 FY27 beat and FY27 guide raise (2026-05-29). Theme classifier still…
Deep-value, heavily-shorted department-store turnaround: Citigroup Buy/$22 (2026-06-01) plus a $190M tariff-refund cash catalyst into a 40%+ short…
Post-earnings-gap premium footwear brand re-rated ~+46% off the $33.45 May-13 low on a $250M accelerated buyback, a Kith capsule "brand heat"…
Freight-cycle inflection play: ~88k carrier authorities exited in 2023-24 and dry-van contract rates turned up again in April 2026, giving…
Post-CRL redemption arc largely complete: stock round-tripped $28.66→$91 high, now $72.62. Live leg is Cushing's second-approval optionality NDA…
Legacy watch maker re-rated ~+37% in a month to all-time highs ($37.73, 2026-06-08) on a 320bp gross-margin beat (Q1 FY27, ~2026-06-04). But the…
Milei reform trade now in its delivery phase: SUPV is the highest-beta Argentine bank ADR on disinflation and credit normalization. Post-midterm…
Fresh freight ACCELERATING but +75% vertical above EVERY analyst PT, RSI 76 blowoff, KNX is the cleaner cluster structure.
Argentina disinflation/reform turnaround accelerating, with BBAR a cluster-confirmed bank vehicle for a credit cycle off a near-zero base. Stock…
Oral-GPCR platform story accelerating: Novo Nordisk obesity deal funds 5 targets, SEP-631 printed positive CSU Phase 1, and SEP-479 hits the ENDO…
Big-box retailer back to positive comps (+2.0% Q1 FY27, 2026-05-28) and repositioning as the physical storefront for the AI-glasses/VR cycle via…
Argentina disinflation/credit-recovery trade; BMA is the best-capitalized domestic vehicle. But the explosive Milei-midterm leg (Oct 2025, ~3x off…
Busted-IPO thrift retailer basing on a trade-down narrative: Q1 (rep. ~2026-05-06) net sales +8.9%, U.S. comps +6.4%, and a 2026-06-02 term-loan…
Deep-cyclical trailer OEM at trough Q1'26 sales −20% YoY, negative gross margin, net debt > market cap. Backlog turned up to $837M (+$132M q/q) on…
Pre-earnings short-squeeze/positioning ramp (+15.8% in May, activist + heavy short interest) into a binary 2026-06-17 Q1 print; consensus models a…
Hospitality vertical-SaaS re-rating off a deep 2025 drawdown: 17th straight record quarter (Q4 rev $82.9M, EPS $0.63 vs $0.50), FY27 guide…
TAVR disruptor at fresh 52w-high but on momentum not news, into a live $250M ATM seller, real binary ~2028 idiosyncratic, MATURING.
Synthetic-DNA tools maker re-rating as a 2nd-order AI-drug-discovery enabler (Complex Genes launch, $1B rev by FY2031, adj-EBITDA breakeven…
Macy's "Bold New Chapter" turnaround printed a clean Q1 beat (EPS $0.13 vs $0.03) and a twice-raised FY guide with growth across every banner,…
Legacy regional-casino operator's digital turnaround is inflecting: after exiting the ESPN Bet money-pit (2025-12-01), iCasino NGR ran +362% YoY…
Medtronic diabetes spinoff repricing as a pure-play automated-insulin-delivery / CGM story; the Abbott dual glucose-ketone exclusive sensor deal…
De-rated former hyper-growth franchise compounder, off ~55% from its late-2024 ~$430 peak as 2024's +20% comps lapped into 2025 deceleration.…
Drive-thru coffee unit-growth story re-accelerating on mobile order-ahead + a hot-food daypart Q1 systemwide comps +8.3% and FY26 guidance raised…
Freight-cycle inflection accelerating: tightening truckload capacity + bid season targeting mid-to-high-single/double-digit contract increases…
Pure M&A special situation: Nuvei is reportedly in advanced talks (Reuters, June 9) to buy Payoneer for ~$2.7B equity value (~$8/sh implied), and…
Defensive med-tech turnaround, MATURING character, no narrative velocity; recovery bounce toward a depressed PT cluster wrong archetype for size.
Process-control toll-taker on the AI buildout: custom-silicon design-start proliferation + advanced packaging (>70% YoY) + re-accelerating memory…
AI-storage sympathy-laggard to DELL, +22% gap to ATH then catalyst spent, FY27 guide only +8%, RSI high-70s cleaner leaders lead.
Spatial-biology re-rate but Atera revenue is a 2027 story, Q1 -3% YoY, -7.3% outside-reversal off the high stretched, post-catalyst, idiosyncratic.
AI-memory ACCELERATING but correlated dup of MU; peak retail-search, PT dispersion $1750-3250, viral DRAM ETF -20% distribution crack memory leg…
AI point-of-care ultrasound narrative accelerating: Q1 2026 revenue +25% YoY ($26.5M), Butterfly Embedded chip-licensing +147%, first FDA-cleared…
"3-mo price move" is the stock's market price change, not an orbyd return.
How this board is built
Every name in the US equity universe is scored on cross-sectional 3-month price momentum by a frontier model and ranked highest-first. The board reflects price moves already made, not a forecast. Each covered name links to its dated research dossier — thesis, invalidation trigger, archetype and catalyst.
Questions
- What are the hottest US stocks right now?
- As of 2026-06-12, the US names with the strongest 3-month price momentum on orbyd are VSXY, ALAB, DELL, CBRL. This is a momentum ranking of price moves already made — research, not advice.
- How is this momentum ranking built?
- A frontier model scores every name in the US equity universe on cross-sectional 3-month price momentum, then ranks them highest-first. Each covered name links to its dated research dossier. Methodology is open.
- Is a high ranking a recommendation?
- No. The board reflects price moves that have already happened, not a forecast or a recommendation. It is educational research, not investment advice.
As of 2026-06-12 · research, not advice.